Skip to content

Investigating the Impact of AI on Shared Decision Making in Post-kidney Transplant Care

Prospective, Randomized Controlled Trial to Investigate the Impact of AI on Shared Decision Making in Post-kidney Transplant Care

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06056518
Acronym
PRIMA-AI
Enrollment
76
Registered
2023-09-28
Start date
2024-01-19
Completion date
2025-10-21
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant Failure

Keywords

Kidney Transplantation, Graft Loss, Kidney Transplant Failure, Riks Prediction System

Brief summary

This study aims to analyze the effects of AI-based risk prediction for graft loss on the frequency of conversations about the treatment after graft loss, as well as the associated shared decision making process in post-kidney transplant care in a German kidney transplant center (KTC), as perceived by the patient, their support person and the clinician/physician. Second, it aims to explore changes in patient and support person recall at 12 months follow-up. Implementation barriers and enablers will also be assessed. The protocol was amended so that the initially planned 24 months observation timeframe was removed from the study and it ended after 12 months due to high attrition and funding restrictions.

Interventions

OTHERAI-based risk prediction for kidney graft loss

Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* written informed consent * patients with functioning kidney allograft * \> 12 months after transplantation * eGFR \< 30 ml/min/1.73m2 according to CKD-EPI 2021 formula * at least 18 years of age * ability to communicate in German * regular follow-up at kidney transplant center

Exclusion criteria

* multi-organ transplantation * eGFR \> 30 ml/min/1.73m2 according to CKD-EPI 2021 formula * \<= 12 months after transplantation * less than 18 years of age * not able to communicate in German * no regular follow-up at kidney transplant center * enrollment in another interventional study less than 1 month before participation in this study

Design outcomes

Primary

MeasureTime frameDescription
Conversation about kidney replacement therapy after graft loss12 monthsProportion of patients, with whom the necessity of kidney replacement therapy after kidney allograft loss is discussed

Secondary

MeasureTime frameDescription
CollaboRATE mean score after 12 months12 monthsCollaboRATE mean score of all study visits from study inclusion until month 12 (values 0 - 9, higher values indicating better outcome)
Control Preferences Scale mean after 12 months12 monthsMean Control Preferences Scale of all study visits from study inclusion until month 12 (values 1 - 5, higher values indicating better outcome)
Kidney replacement therapy 12 months12 monthsFrequency of kidney replacement therapy after graft loss 12 months
Emergency dialysis 12 months12 monthsFrequency of emergency dialysis after graft loss 12 months
Dialysis initiation via AV-shunt 12 months12 monthsFrequency of dialysis initiation via AV-shunt after graft loss 12 months
Dialysis initiation via permanent catheter 12 months12 monthsFrequency of dialysis initiation via permanent catheter after graft loss 12 months
Retransplantation 12 months12 monthsFrequency of retransplantation after graft loss 12 months

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORKlemens Budde, MD

Charite University, Berlin, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026